How Recombinant LAL Reagents Differ From Each Other

Animal-derived reagents have long been the standard for bacterial endotoxin testing in parenteral drug development, but recombinant alternatives are gaining regulatory ground. Two distinct types are now commercially available, and they are not interchangeable: each has a different mechanism, a different regulatory history, and a different standing across major pharmacopeias. That distinction matters because compendial acceptance is not yet harmonized globally, and the validation path for one reagent type does not automatically satisfy requirements for another. For pharmaceutical and biotech manufacturers developing products for multiple markets, understanding these differences early reduces the risk of costly late-stage method changes.

Read the full article to understand how the two reagent types compare and what that means for your testing strategy.